What question did this study set out to answer?

This study evaluates the outcomes of patients diagnosed with mycosis fungoides and Sézary syndrome based on treatment center type.

December 8, 2025BloodOpen Access

Comparative outcomes of 14,650 patients with mycosis fungoides/Sézary syndrome from academic and community cancer programs

View Full Paper

Ask AI

Bookmark

This study evaluates the outcomes of patients diagnosed with mycosis fungoides and Sézary syndrome based on treatment center type.
Retrospective review of 14,650 cases from the National Cancer Data Base between 2004 and 2022.
Comparison of demographics and survival data between academic cancer programs and community cancer programs.
Utilization of Kaplan-Meier and Cox models for overall survival analysis, adjusting for various factors.
Patients at academic cancer programs had significantly better adjusted median survival (14 years vs 11 years).
Higher overall survival rates recorded at academic programs at 2 years (88.7% vs 82.2%), 5 years (75% vs 68%), and 10 years (61% vs 32%).
More patients at community cancer programs received chemotherapy and radiation therapy, as well as a higher diagnosis rate of stage IV.

No takes yet. Share an insight, caveat, or question.

Retrospective analysis shows better survival outcomes in mycosis fungoides patients treated at academic programs compared to community care.

Velázquez et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis shows better survival outcomes in mycosis fungoides patients treated at academic programs compared to community care.